Kura Oncology, Inc.
KURA· Nasdaq
Released Mar 5, 2026, before the open
10-K filed Mar 5, 2026, 64 days after period end · 0001193125-26-092567
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $17.34M | — | — | — |
| Net Income | -$81.00M |
Kura Oncology, Inc. · CIK 1422143 · Engraved from SEC EDGAR
| -$19.22M |
| -$42.79M |
| -$33.11M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.